Regeneron (REGN) Says EMA Accepted Review for Otarmeni Application

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 10 Best Debt-Free S&P 500 Stocks to Buy Now. On May 22, 2026, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced that the European Medicines Agency accepted for review under Accelerated Assessment the Marketing Authorization Application for Otarmeni, an in vivo adeno-associated virus vector-based gene therapy for biallelic OTOF variant-associated […]